1463 Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): randomized, phase 3 KEYVIBE-008

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Biology

Cancer Oncology

Medicine

Paleontology

Internal Medicine

Show all topics

DOI

10.1136/jitc-2024-sitc2024.1463

License

CC-BY-NC

Other Formats

PDF